- Home
- TYG vs CELC Comparison
TYG vs CELC Comparison
Compare TYG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYG
- CELC
- Stock Information
- Founded
- TYG 2003
- CELC 2011
- Country
- TYG United States
- CELC United States
- Employees
- TYG N/A
- CELC N/A
- Industry
- TYG Investment Managers
- CELC Medical Specialities
- Sector
- TYG Finance
- CELC Health Care
- Exchange
- TYG Nasdaq
- CELC Nasdaq
- Market Cap
- TYG 441.8M
- CELC 440.0M
- IPO Year
- TYG N/A
- CELC 2017
- Fundamental
- Price
- TYG $42.58
- CELC $11.60
- Analyst Decision
- TYG
- CELC Strong Buy
- Analyst Count
- TYG 0
- CELC 5
- Target Price
- TYG N/A
- CELC $30.80
- AVG Volume (30 Days)
- TYG 54.9K
- CELC 140.7K
- Earning Date
- TYG 01-01-0001
- CELC 08-13-2025
- Dividend Yield
- TYG 9.55%
- CELC N/A
- EPS Growth
- TYG N/A
- CELC N/A
- EPS
- TYG 19.59
- CELC N/A
- Revenue
- TYG $13,675,460.00
- CELC N/A
- Revenue This Year
- TYG N/A
- CELC N/A
- Revenue Next Year
- TYG N/A
- CELC N/A
- P/E Ratio
- TYG $2.17
- CELC N/A
- Revenue Growth
- TYG N/A
- CELC N/A
- 52 Week Low
- TYG $32.90
- CELC $7.58
- 52 Week High
- TYG $48.76
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- TYG 62.21
- CELC 49.88
- Support Level
- TYG $41.72
- CELC $11.85
- Resistance Level
- TYG $43.29
- CELC $13.40
- Average True Range (ATR)
- TYG 0.71
- CELC 0.70
- MACD
- TYG 0.08
- CELC -0.09
- Stochastic Oscillator
- TYG 76.41
- CELC 35.83
About TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.